ABAXIS Announces Launch of the First Fully Automated Canine Wellness Profile That Includes a Canine Heartworm An...(tatements that constitute forward-looki...),Health

Date:10/8/2009

tatements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance of new or planned product offerings, process improvements and product manufacturing quality and efficiencies in future production of our products. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed under "Risk Factors" in Abaxis' Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertak
'/>"/>

SOURCE Abaxis, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
2. Curemark Announces Senior Executive Promotions
3. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
4. MedShape Solutions, Inc. Appoints Jack Blair and Tom Hills to Board of Directors; Announces Additions to Management Team
5. Odyssey Thera Announces Achievement of Pfizer Drug Candidate Milestones
6. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
7. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
8. BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call
9. BD Announces FDA 510(k) Clearance of BD Vacutainer(R) Rapid Serum Blood Collection Tube
10. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
11. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350